Physically simulating human organs on computer chips in a lab setting and studying their reactions to drugs and other stimuli could be the future of medical research.
Imagine using stem cells to rebuild the heart following severe heart failure or coronary heart disease. James T. Willerson, MD, President and Medical Director of the Texas Heart Institute at St. Luke’s…
Recent Videos in Cardiology: Non-Interventional Page 5
NEW YORK (Reuters Health) – Elderly patients with heart failure have an increasing mortality risk as their dose of furosemide increases, after taking into account multiple confounders, a…
NEW YORK (Reuters Health) – Coronary heart disease that continues to progress to serious events in patients whose LDL levels have been brought down adequately — called “residual…
NEW YORK (Reuters Health) – Recommendations issued by the European Society of Cardiology emphasize the need to consider the clinical context in interpreting cardiac troponin readings in acute…
NEW YORK (Reuters Health) – Rates of major adverse cardiovascular events (MACEs) are lower in hypertensive patients with coronary artery disease on amlodipine when candesartan is added to…
NEW YORK (Reuters Health) – For patients with diabetes and hypertension, an antihypertensive regimen combining an ACE inhibitor with a calcium channel blocker provides better protection against cardiovascular…
NEW YORK (Reuters Health) – Even though carotid intima media thickness (cIMT) independently predicts cardiovascular disease events, this parameter does not add useful information to traditional risk factor…
NEW YORK (Reuters Health) – Performing percutaneous coronary interventions (PCI) in non-infarct-related coronary vessels along with primary PCI for ST-segment elevation myocardial infarction (STEMI) appears to jeopardize patient…
NEW YORK (Reuters Health) – Despite its widespread use, there is no conclusive evidence that oxygen therapy benefits patients with acute myocardial infarction (AMI), according to a paper…
NEW YORK (Reuters Health) – The new-generation zotarolimus-eluting coronary stent was as safe and effective after 13 months’ follow-up as the everolimus-eluting stent in a study with minimal…
NEW YORK (Reuters Health) – The novel antiarrhythmic agent vernakalant is a safe and effective agent for pharmacologic conversion of recent-onset atrial fibrillation (AF) in hemodynamically stable patients,…
